Session 37 - 12th CROI

Home

Session 37 Oral Abstracts
Antiretroviral Therapy: New Agents, New Combinations, and Virologic Responses
Friday, 10 am - 12:30 pm
Auditorium

10:00 am 156	Identification and Biochemical Characterization of a New Class of HIV Inhibitors: Nucleotide-competing Reverse Transcriptase Inhibitors Dirk Jochmans*¹, B Kesteleyn¹, B Marchand², M Götte², T Ivens¹, P Dehertogh¹, A Peeters¹, R Pauwels³, P Wigerinck¹, and K Hertogs¹ ¹Tibotec, Mechelen, Belgium; ²McGill Univ. AIDS Ctr., Montreal, Canada; and ³St-Légier, Switzerland
10:15 am 157	Crystal Structure of a Complex of HIV-1 Reverse Transcriptase with an RNase H Inhibitor Bound at a Novel Site on the Enzyme Daniel M Himmel*¹, S Sarafianos¹, A Clark, Jr¹, M Parniak², S Hughes³, and E Arnold¹ ¹Ctr for Advanced Biotech and Med, Rutgers Univ, Piscataway, NJ, USA; ²Univ of Pittsburgh Sch of Med, PA, USA; and ³NCI-FCRDC, Frederick, MD, USA
10:30 am 158	Therapeutic Inhibition of SIV Replication in Macaques by GR Blockade and Implications for Therapy of HIV-1 K Muthumani¹, J Boyer¹, A Choo¹, D Hwang¹, K Thieu¹, R Parkinson¹, E Nietrzeba¹, J Kim², M Lewis³, and David Weiner*¹ ¹Univ of Pennsylvania, Philadelphia, USA; ²VGX Pharma, Philadelphia, PA, USA; and ³Bioqual, Inc, Rockville, MD, USA
10:45 am 159	PA-457, the First-in-class Maturation Inhibitor, Exhibits Antiviral Activity following a Single Oral Dose in HIV-1-infected Patients David Martin*¹, J Jacobson², D Schurmann³, E Osswald⁴, J Doto¹, C Wild¹, and G Allaway¹ ¹Panacos Pharma, Inc, Gaithersburg, MD, USA; ²Beth Israel Deaconess Med Ctr, Boston, MA, USA; ³Univ Med Berlin, Germany; and ⁴Clin Res, Berlin, Germany
11:00 am 160	TMC278: Potent Anti-HIV Activity in Antiretroviral Therapy-naïve Patients Frank Goebel*¹, A Yakovlev², A Pozniak³, E Vinogradova⁴, P Lewi⁵, G Boogaerts⁶, R Hoetelmans⁶, M P De Béthune⁶, M Peeters⁶, and B Woodfall⁶ ¹Ludwig Maximilians Univ, Munich, Germany; ²Hosp Botkin St Petersburg, Russia; ³Chelsea and Westminster Hosp, London, UK; ⁴Ctr for AIDS & Infectious Diseases, St Petersburg, Russia; ⁵Janssen Pharma, Vosselaar, Belgium; and ⁶Tibotec, Mechelen, Belgium
11:15 am 161	Antiretroviral Effect of L-000870810, a Novel HIV-1 Integrase Inhibitor, in HIV-1-infected Patients Susan Little*¹, G Drusano², R Schooley³, D Haas⁴, P Kumar⁵, S Hammer⁶, D McMahon⁷, K Squires⁸, R Asfour¹, D Richman¹, J Chen⁹, A Saah⁹, R Leavitt⁹, D Hazuda⁹, B Y Nguyen⁹, and Protocol 004 Study Team ¹Univ of California, San Diego, USA; ²Albany Med Coll, NY, USA; ³Univ of Colorado, Denver, USA; ⁴Vanderbilt Univ Med Ctr, Nashville, TN, USA; ⁵Georgetown Univ, Washington, DC, USA; ⁶New York Presbyterian Hosp, NY, USA; ⁷Univ of Pittsburgh, PA, USA; ⁸Los Angeles County, Univ of Southern California Med Ctr, USA; and ⁹Merck Res Labs, West Point, PA, USA
11:30 am 162	Randomized, Controlled Trial of Lopinavir/Ritonavir + Efavirenz vs Efavirenz + 2 Nucleoside Reverse Transcriptase Inhibitors following a First Suppressive 3- or 4-Drug Regimen in Advanced HIV Disease Margaret Fischl*¹, R Bassett², A Collier³, L Mukherjee², L Demeter⁴, P Tebas⁵, M Giuliano⁶, K Garren⁷, B Brizz⁸, J Feinberg⁹, and Adult AIDS Clinical Trials Group ¹Univ of Miami, FL, USA; ²Harvard Sch of Publ Hlth, Boston, MA, USA; ³Univ of Washington, Seattle, USA; ⁴Univ of Rochester Med Ctr, NY, USA; ⁵Univ of Pennsylvania, Philadelphia, USA; ⁶Inst Superiore di Sanita, Rome, Italy; ⁷Abbott Labs, Abbott Park, IL, USA; ⁸Social & Sci Systems, Inc, Silver Spring, MD, USA; and ⁹Univ of Cincinnati Med Ctr, OH, USA
11:45 am 163	The Level of Persistent Viremia Less Than 50 copies/mL in Patients on Suppressive Antiretroviral Therapy Is Independent of Regimen Potency but Strongly Associated with Pretreatment Viremia Sarah Palmer*¹, A Wiegand¹, F Maldarelli¹, J Omachi², S Brun², D Kempf², M King², J Coffin¹, and J Mellors³ ¹NCI-Frederick, NIH, DHHS, MD, USA; ²Abbott Labs, Abbott Park, IL, USA; and ³Univ of Pittsburgh, PA, USA
12:00 pm 164LB	Efficacy of TMC114/r in 3-Class Experienced Patients with Limited Treatment Options: 24-Week Planned Interim Analysis of 2 96-week Multinational Dose-finding Trials C Katlama¹, D Berger², N Bellos³, B Grinsztejn⁴, Richard Haubrich*⁵, T Wilkin⁶, J M Molina⁷, C Steinhart^8,9, R Pedro¹⁰, M P de Béthune¹¹, S De Meyer¹¹, R Hoetelmans¹¹, W Parys¹², T Vangeneuden¹¹, and E Lefebvre¹² ¹Hosp Pitie-Salpetriere, Paris, France; ²Univ of Illinois, Chicago, USA; ³Southwest Infectious Disease Associates, Dallas, TX, USA; ⁴Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brasil; ⁵Univ of California, San Diego, USA; ⁶Weill Med Coll, Cornell Univ, New York, NY, USA; ⁷Hosp St-Louis, Paris, France; ⁸Steinhart Medical Associates, Miami, FL, USA ; ⁹Mercy Hospital, Miami, FL, USA; ¹⁰UNICAMP, Campinas, Brazil; ¹¹Tibotec, Mechelen, Belgium; and ¹²Tibotec, Yardley, PA, USA
12:15 pm 165LB	Virological and Immunological Outcomes at 3 Years following Initiation of ART with Regimens Containing a NNRTI or PI or both: The INITIO Trial D Cooper¹ and Patrick Yeni*² ¹Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia and ²Hôpital Bichat, University of Paris, France